Saturday, October 02, 2010

ACTC, Advanced Cell Technology Updates on Myoblast

September 29th, Advanced Cell Technology releases update on Phase I of its human clinical trials. ACTC reported that they are in the process of reviewing the results of four independent studies.

"We believe our phase II study would represent one of the most advanced stem cell studies conducted to date," said William M. Caldwell IV, ACT's Chairman and CEO. "In addition to evaluating our clinical options, the Company is also considering the most effective way to finance the cost of the study, which could include grants, partnerships or capital provided by foundations. We are also in negotiations with several countries in Europe to conduct a similar trial. The market potential in the EU is even greater than in the U.S. by up to 50% in patient population size by some estimates."

ACTC has been cleared by the FDA to proceed to phase II trial expected to begin in the second half of 2011.

PennyMarkets contributors are not registered investment advisers.  Always consult a registered investment advisor prior to making any investment.  Investments in pennystocks can result in entire loss of investment.

No comments: